ArticleTherapeutic advances in medical oncology2026
Tumors >2 cm in node-negative, HER2-positive breast cancer: comparing neoadjuvant dual-targeted versus adjuvant single-targeted treatment pathways in real-world practice.
Xiaoduo Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.